Risk of Anaphylaxis After Vaccination of Children and Adolescents
Kari Bohlke, Robert S. Thompson(Group Health Cooperative), Frank DeStefano(Abbott Fund), Robert L. Davis(Southeast Health District), John P. Mullooly(Kaiser Permanente Center for Health Research), Steven Black(Kaiser Permanente), S. Michael Marcy(Kaiser Foundation Hospital), M. Miles Braun(Center for Biologics Evaluation and Research)
Cited by 321
Related Papers
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
|New England Journal of Medicine|2001|3.7k
Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
|Arthritis & Rheumatism|2002|661
Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline
|Journal of Clinical Oncology|2022|608
Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group
|Annals of Allergy Asthma & Immunology|2006|482
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
|Annals of Internal Medicine|2003|459